

## **Response Biomedical Corporation Schedules Third Quarter 2012 Earnings Release and Announces Conference Call**

### **FOR IMMEDIATE RELEASE**

VANCOUVER, British Columbia – November 7, 2012

Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) will release its financial results for the period ending September 30, 2012 after markets close on Wednesday, November 14, 2012.

Jeffrey L. Purvin, Chief Executive Officer, will host a conference call on Wednesday, November 14, 2012 at 2:00 p.m. PST (5:00 p.m. EST) to discuss the Company's third quarter 2012 financial results. Also participating in the call will be Bill Adams, Chief Financial Officer.

The conference call will be webcast live and is also available by dialing 1-877-644-1289 in North America or 1-914-495-8554 for all other locations. The conference ID number is 43772173 and participants are encouraged to initiate their calls at least 10 minutes in advance of the 2:00 p.m. PST start time to ensure a timely connection.

The webcast and earnings release will be accessible at: Response Biomedical - Events Calendar: Corporate. A replay of the conference call will also be available there approximately two hours after the call and for 90 days thereafter.

### **About Response Biomedical**

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® platform for clinical, biodefense, and environmental applications. RAMP® represents a new paradigm in diagnostics that provides laboratory quality results in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP® system consists of a reader and single-use disposable test cartridges and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP® clinical tests are commercially available for the early detection of heart attack, congestive heart failure, Influenza A+B and RSV through our commercial partners and distributors.

In the non-clinical market, RAMP® tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response has achieved CE Marking for its readers and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2008.

Response Biomedical is a publicly traded Company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at [www.responsebio.com](http://www.responsebio.com).

### **About the RAMP® Reader and RAMP® 200 Reader**

The RAMP® enabling platform is a portable, scanning fluorescence, quantitative analysis platform for near-patient testing that enables rapid and robust quantitative results. The platform includes easy software upgrades, data management capabilities and unique interface options. The RAMP® Reader features a small footprint and attractive ease of use for moderate throughput settings. The RAMP® 200 Reader has innovative design features, including multi-port capability to run 12 tests per hour on one module and up to 36 tests per hour using three modules. This allows tests to be run for multiple patients simultaneously or multiple assays to be run for one patient. More information on our proprietary RAMP® technology can be found at [www.responsebio.com](http://www.responsebio.com).

### **Forward-Looking Statements**

Certain statements contained in this news release constitute forward-looking information or forward-look statements (collectively, "forward-looking statements") with the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as "believe", "may", "will", "project", "anticipate", "continue", "estimate", "expect", "intend" and other similar words suggesting future events or future performance. Forward-looking statements are made based on assumptions made by the Company regarding various matters. Although the Company believes the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct.

Readers should not place undue reliance on these statements. Actual events or results may differ materially. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many factors may cause the Company's actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual report on Form 10-K, our quarterly reports on Form 10-Q, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities.

The forward-looking statements contained in this news release are current as of the date hereof and are qualified in their entirety by this cautionary statement. Except as expressly required by applicable securities laws, the Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

**Response Biomedical Corp.:**  
Patricia Massitti, 604-456-6010

VP, Administration & Corporate Communications  
pmassitti@responsebio.com